Evidence is mounting that something happens when youth start working that compels them to smoke. With this trend in mind, it's worth exploring potential strategies to prevent smoking among youth who enter the workforce.
The study's goal was to examine the impact of parent and peer relationships on health behaviors and psychological well-being of those with and without Type 1 diabetes over the transition to emerging adulthood.
“Graphic warning labels” pair gruesome images with warnings about the dangers of smoking, covering anywhere from 30 to 80 percent of cigarette pack “faces” (the front and back). Do they prevent people from starting to smoke or cause current smokers to quit?
CVS has officially stopped selling cigarettes and other tobacco products, a move that will cost the pharmacy chain about $2 billion in annual profits. It's difficult to say if this will affect smoking. For now, the ban is most significant for what it represents symbolically.
The PROMIS Smoking Initiative developed an assessment toolkit that enables the measurement of current adult smokers' standing in domains of importance to smoking research, including nicotine dependence and using smoking to cope with stress.
This paper describes development of Positive Emotional and Sensory Expectancies of Smoking item banks that will serve to standardize the assessment of this construct among daily and nondaily cigarette smokers.
The Patient-Reported Outcomes Measurement Information System (PROMIS®) Smoking Initiative has developed 6 item banks for assessing smoking behaviors and biopsychosocial correlates of smoking among daily and nondaily adult cigarette smokers.
Smoking is a coping strategy for many smokers who then have difficulty finding new ways to cope with negative affect when they quit. This paper describes analyses conducted to develop and evaluate item banks for assessing the coping expectancies of smoking for daily and nondaily smokers.
At this point, asking the FDA to restrict marketing or to ban flavored products would be premature. The base of scientific evidence is growing, particularly with e-cigarettes, but it doesn't support additional regulatory action beyond what the FDA has already proposed.